1-179552619-CTT-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_014625.4(NPHS2):c.855_856delAA(p.Arg286fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000136 in 1,613,646 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000092 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00014 ( 0 hom. )
Consequence
NPHS2
NM_014625.4 frameshift
NM_014625.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.66
Genes affected
NPHS2 (HGNC:13394): (NPHS2 stomatin family member, podocin) This gene encodes a protein that plays a role in the regulation of glomerular permeability. Mutations in this gene cause steroid-resistant nephrotic syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]
AXDND1 (HGNC:26564): (axonemal dynein light chain domain containing 1)
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 53 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-179552619-CTT-C is Pathogenic according to our data. Variant chr1-179552619-CTT-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 188823.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-179552619-CTT-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.855_856delAA | p.Arg286fs | frameshift_variant | 7/8 | ENST00000367615.9 | NP_055440.1 | |
AXDND1 | NM_144696.6 | c.3032-1891_3032-1890delTT | intron_variant | ENST00000367618.8 | NP_653297.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.855_856delAA | p.Arg286fs | frameshift_variant | 7/8 | 1 | NM_014625.4 | ENSP00000356587.4 | ||
AXDND1 | ENST00000367618.8 | c.3032-1891_3032-1890delTT | intron_variant | 1 | NM_144696.6 | ENSP00000356590.3 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152184Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
14
AN:
152184
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000680 AC: 17AN: 250072Hom.: 0 AF XY: 0.0000739 AC XY: 10AN XY: 135240
GnomAD3 exomes
AF:
AC:
17
AN:
250072
Hom.:
AF XY:
AC XY:
10
AN XY:
135240
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000141 AC: 206AN: 1461462Hom.: 0 AF XY: 0.000127 AC XY: 92AN XY: 727018
GnomAD4 exome
AF:
AC:
206
AN:
1461462
Hom.:
AF XY:
AC XY:
92
AN XY:
727018
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152184Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74356
GnomAD4 genome
AF:
AC:
14
AN:
152184
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
74356
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:16
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Nephrotic syndrome, type 2 Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jan 03, 2020 | NM_014625.2(NPHS2):c.855_856delAA(R286Tfs*17) is classified as pathogenic in the context of NPHS2-related nephrotic syndrome. Sources cited for classification include the following: PMID 11805166, 18823551, 19406966, 24742477 and 15327385. Classification of NM_014625.2(NPHS2):c.855_856delAA(R286Tfs*17) is based on the following criteria: The variant causes a premature termination codon that is not expected to be targeted by nonsense-mediated mRNA decay; however, literature evidence strongly supports pathogenicity. Please note: this variant was assessed in the context of healthy population screening. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2000 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 01, 2018 | Variant summary: NPHS2 c.855_856delAA (p.Arg286ThrfsX17) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 6.5e-05 in 275798 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in NPHS2 causing Nephrotic Syndrome, Type 2 (6.5e-05 vs 0.0018), allowing no conclusion about variant significance. c.855_856delAA has been reported in the literature in multiple individuals affected with Steroid Resistant Nephrotic Syndrome. These data indicate that the variant is very likely to be associated with disease. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 09, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 13, 2021 | - - |
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 15, 2022 | Frameshift variant in the C-terminus predicted to result in protein truncation, as the last 98 amino acids are lost and replaced with 16 incorrect amino acids (HGMD); This variant is associated with the following publications: (PMID: 24227627, 18823551, 12464671, 30295827, 15769810, 15327385, 15253708, 15322893, 30260545, 30655312, 25949442, 14978175, 11805166, 10742096, 17699384, 19145239, 32581362, 33144682, 31589614, 33226606) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 26, 2023 | This sequence change creates a premature translational stop signal (p.Arg286Thrfs*17) in the NPHS2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 98 amino acid(s) of the NPHS2 protein. This variant is present in population databases (rs749740335, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with steroid resistant nephrotic syndrome (PMID: 11805166, 18823551, 20947785, 21355056, 24509478). ClinVar contains an entry for this variant (Variation ID: 188823). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 01, 2017 | - - |
Focal segmental glomerulosclerosis Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Dec 30, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Jan 17, 2019 | - - |
Nephrotic range proteinuria Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Chronic kidney disease Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Cavalleri Lab, Royal College of Surgeons in Ireland | May 28, 2020 | PVS1, PM3 - |
Steroid-resistant nephrotic syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
NPHS2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 20, 2024 | The NPHS2 c.855_856delAA variant is predicted to result in a frameshift and premature protein termination (p.Arg286Thrfs*17). Also known as Q285fsX302 or R285fx302X, this variant has been reported to be pathogenic for steroid-resistant nephrotic syndrome (SRNS) (Boute et al. 2000. PubMed ID: 10742096; Machuca et al. 2009. PubMed ID: 19145239; Santín et al. 2011. PubMed ID: 20947785). This variant is reported in 0.016% of alleles in individuals of European (non-Finnish) descent in gnomAD. Frameshift variants in NPHS2 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at